Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its [tariff rollout]( ...

CEO David Joyner tells Yahoo Finance he's working to define the company. President Trump ... which suggests that Eli Lilly’s... GLP-1 drug prices are falling. That's good news for patients ...

referring to those older drugs. He spoke after Eli Lilly reported first-quarter earnings and 2025 guidance, which did not include estimated effects of the potential pharmaceutical tariffs.

Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to ...